BioLineRx (BLRX) Operating Expenses (2023 - 2025)
Historic Operating Expenses for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$2.6 million.
- BioLineRx's Operating Expenses rose 3552.47% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 3247.84%. This contributed to the annual value of -$15.5 million for FY2024, which is 1783.95% up from last year.
- According to the latest figures from Q3 2025, BioLineRx's Operating Expenses is -$2.6 million, which was up 3552.47% from -$2.5 million recorded in Q2 2025.
- BioLineRx's 5-year Operating Expenses high stood at -$2.5 million for Q2 2025, and its period low was -$5.3 million during Q4 2023.
- Its 3-year average for Operating Expenses is -$3.8 million, with a median of -$3.9 million in 2024.
- As far as peak fluctuations go, BioLineRx's Operating Expenses skyrocketed by 641.27% in 2024, and later skyrocketed by 3552.47% in 2025.
- Quarter analysis of 3 years shows BioLineRx's Operating Expenses stood at -$5.3 million in 2023, then rose by 28.79% to -$3.8 million in 2024, then skyrocketed by 32.56% to -$2.6 million in 2025.
- Its Operating Expenses stands at -$2.6 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$2.6 million for Q1 2025.